XVIE to Treat Androgenetic Alopecia (AGA)
A Phase I/II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Potential Efficacy of XVIE Injected Intradermally in Patients With Androgenetic Alopecia
In the register
The register attaches this trial to Xvie (amniotic fluid injectable) (Xtressé), currently at “Phase 1/2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Not yet recruiting
- Declared phase
- Phase 1/2
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
- Participants (registry)
- 30
- Start
- December 2026 (planned)
- Primary completion
- May 2028 (planned)
- Study completion
- May 2028 (planned)
- Last registry update
- August 2026
- Countries
- United States
Conditions studied: Androgenetic Alopecia
Interventions: Decellularized allogeneic human amniotic fluid, Sodium chloride 0.9% injectable solution
Other trials of Xvie (amniotic fluid injectable)
- NCT07221773Enrolling by invitation
Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.